Replies to post #134515 on Biotech Values

[DewDiligence]

BIIB/ELN—He thinks that there will be switching to BG12, once approved, of patients on Tysabri that are JCV+ and who have been on drug for years.

That’s not exactly going out on a limb! The real question is what becomes of patients who are JCV-negative—hence my question in #msg-70615422.